Cadherin-11 Inhibitors to Treat Poor Prognosis Cancers

Categories: “Cancer Therapeutics

Reference #: 2009-009

OTC Contact: Ruchika Nijhara, Ph.D., MBA, CLP (Directory Information | Send a Message)


Cadherin-11, a mesenchymal cadherin associated with basal-like breast cancers and invasive cells but not expressed in normal epithelia, aligns with clinical outcome in poor prognosis cancers. The present invention describes novel compounds that inhibit Cadherin-11 and their use as potential therapeutics for poor prognosis carcinomas.

Potential therapeutics for breast cancer, prostate cancer, renal cancer, multiple myeloma, glioblastoma.


Stage of Development

A lead compound has been evaluated in a breast cancer model. Preliminary studies have been done to validate the target for glioblastoma multiforme (GBM). The inhibitor demonstrated high specificity for only Cadherin-11 expressing cells.


Milton L Brown, Stephen Byers, Sivanesan Dakshanamurthy and Jaime Guidry

Patent Status

Applications are pending